06/03/2026
https://www.facebook.com/share/p/1BT9tT8MgF/
A future where missing teeth could be replaced by growing new ones may be one step closer.
Japanese dental startup Toregem has secured $5.3 million in new funding to advance Phase II human trials of TRG035, an experimental tooth-regrowth treatment.
The therapy is being developed for people with congenital tooth agenesis, a rare condition in which one or more permanent teeth never develop. For many patients, treatment currently relies on dentures, bridges, or dental implants.
TRG035 is designed to block a protein called USAG-1, which researchers believe may help activate natural tooth-development pathways and stimulate the growth of new teeth. The long-term goal is to develop a treatment capable of inducing a "third dentition" after the permanent teeth have already formed.
The new funding will support ongoing clinical trials in Japan, future development plans in the United States, and continued research into regenerative dental medicine.
While the treatment remains experimental and is not yet available to patients, it is among the most advanced tooth-regeneration therapies currently being tested in humans.
If successful, it could one day offer a completely new treatment option for people born with missing teeth.
Source: Toregem BioPharma (Official Company Announcement, May 2026)